SK discovery

SK discovery is a South Korean publicly traded holding company within SK Group that oversees a portfolio spanning vaccines/pharmaceuticals, plasma-derived therapeutics, healthcare, chemicals, energy, and real estate. Its healthcare exposure is primarily through subsidiaries including SK bioscience, which markets and develops vaccines, SK plasma, which manufactures plasma-derived blood products, and SK chemicals, which operates a life sciences business alongside green chemicals. The group therefore participates in commercial-stage biopharma markets including influenza, shingles, varicella, pneumococcal, typhoid, rotavirus, hemophilia, and immunodeficiency-related products and development programs. For a biotech analyst, SK discovery is best viewed not as a single-product biotech developer but as a diversified strategic holding company with meaningful life science assets, manufacturing infrastructure, and commercialization capabilities anchored in Korea.